Alert: New Earnings Report (11/8/23)-Xenon Pharmaceuticals Inc (NASDAQ: XENE).


Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported a loss for its third fiscal quarter (ending September 30) of $-0.73 versus a loss $-0.57 for the same period a year ago. This result exceeded the consensus estimate of $-0.75 by $0.02. For the latest four quarters through September 30, E.P.S. were $-2.66 versus $-2.06 for the same period a year ago.


Recent Price Action

Xenon Pharmaceuticals Inc (NASDAQ: XENE) stock increased 1.1% on 11/8/23. The shares closed at $32.15. The stock has performed in line with the market over the last nine months and has risen 3.7% during the last week.

Current PriceTarget Research Rating

Reflecting future returns on capital that are forecasted to fall short of the cost of capital, XENE is expected to be a modest Value Eraser.

Xenon Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. Xenon Pharmaceuticals has a slightly negative Power Rating of 40 and a very low Appreciation Score of 12, with the Lowest Value Trend Rating the result.

Rating Review

In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.

Be the first to comment

Leave a Reply

Your email address will not be published.